NCT03057847View on ClinicalTrials.gov

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

February 24, 2022

Study Completion Date

February 24, 2022

Conditions
Hepatitis C, ChronicOpioid-use Disorder
Interventions
DRUG

Sofosbuvir/Velpatasvir

Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period

Trial Locations (1)

15213

Magee Womens Hospital of UPMC, Pittsburgh

All Listed Sponsors
lead

Elizabeth Krans, MD

OTHER

NCT03057847 - Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection | Biotech Hunter | Biotech Hunter